"For the informed" a positive interim analysis is not significantly in question. From this my thought is that the positive result is already some what built into the current share price and when the results are known the price will bounce but not skyrocket. However if a number of positive events occur within a short time frame that could be fun. It is possible.
Interim analysis will once again validate the science. It will not provide the opportunity to receive revenue from treating patients. Only approval will provide that and 2017 to 2018 is the time frame for approval for DCVax-L.
... very short form- this thing is currently aimed at $0.80. The science is not the problem. For the informed it is not even in question. The problem is cash flow. At eighty cents a share there are not enough shares to fund this thing to DCVax-L approval ( in 2018?). Not to mention Phase 2 for Direct. The only hope is for the conceptual partners to come up with some very significant up front money to ante in to the science wise extremely promising NW Bio. game. If you buy into that hope and there is ample precedence to support that position buy at eighty cents which is a bottom channel line - four months old - and hopefully strong support. TWT.
Total bs. The article referred to was posted July 15,2015 when the share price was $11.5 and Zacks valuation for the following YOY was $16.00. It is currently $8.00. For what it is worth.
momentum- you've got to try harder.
Linda and her associates are by far the biggest shareholders. If she were to cheat the shareholders she would be cheating herself. Just one more of those inconvenient truths you lame bashers keep trying to ignore.
Pretty much summarizes "...The Chartists..." post of March 23- Four weeks ago. Note the continuing significance of the $1.84/1.85 resistance line. Accident or intentional sign? Question of the day.
... bought another thousand shares. Only 1600 from my desired minimum holding. Next buy will be off the bottom B.B. or off a rising trend line. Either will work.
e. "a" above is two weeks later than expected, still it is in play today. The big run up in the general market is over the hill and on the way down. "Biotechs without news usually follow the market" quote me.
f. "b" above remains a happy dream.
g. "c" above is decidedly still in play. Two and a half million shares today. Breaking out on high volume?
h. This is getting fun again.
Maybe the halt to enrollment occurred because a recommendation for stopping the trail for efficacy was received. Although it was turned down in favor of completing the trial the fact of the recommendation along with the exemplary side effect profile was enough to convince the FDA to allow the trial to continue with a lowered total enrollment. And of course there can be no discussion regarding the ongoing trial. Thus the required and prolonged silence with respect to Linda's " good news".
Please email this excellent summary directly to Linda, Les and every one of the officers and board members. Put it right in their faces where they can't pretend to ignore this important message.